| Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa … E Ngaimisi, A Habtewold, O Minzi, E Makonnen, S Mugusi, W Amogne, ... PloS one 8 (7), e67946, 2013 | 147 | 2013 |
| High plasma efavirenz level and CYP2B6* 6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective … G Yimer, W Amogne, A Habtewold, E Makonnen, N Ueda, A Suda, ... The pharmacogenomics journal 12 (6), 499-506, 2012 | 128 | 2012 |
| Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients G Yimer, N Ueda, A Habtewold, W Amogne, A Suda, KD Riedel, ... PLoS One 6 (12), e27810, 2011 | 125 | 2011 |
| Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients G Yimer, M Gry, W Amogne, E Makonnen, A Habtewold, Z Petros, ... PloS one 9 (4), e94271, 2014 | 82 | 2014 |
| Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients A Habtewold, W Amogne, E Makonnen, G Yimer, KD Riedel, N Ueda, ... Journal of antimicrobial chemotherapy 66 (10), 2350-2361, 2011 | 72 | 2011 |
| Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients A Habtewold, W Amogne, E Makonnen, G Yimer, H Nylen, KD Riedel, ... The pharmacogenomics journal 13 (6), 484-489, 2013 | 54 | 2013 |
| β-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans RJ Hardwick, W Amogne, S Mugusi, G Yimer, E Ngaimisi, A Habtewold, ... The Journal of infectious diseases 206 (7), 1012-1019, 2012 | 52 | 2012 |
| Efficacy and safety of antiretroviral therapy initiated one week after tuberculosis therapy in patients with CD4 counts< 200 cells/μL: TB-HAART study, a randomized clinical trial W Amogne, G Aderaye, A Habtewold, G Yimer, E Makonnen, A Worku, ... PLoS One 10 (5), e0122587, 2015 | 44 | 2015 |
| HLA-B* 57 allele is associated with concomitant anti-tuberculosis and antiretroviral drugs induced liver toxicity in ethiopians Z Petros, J Kishikawa, E Makonnen, G Yimer, A Habtewold, E Aklillu Frontiers in pharmacology 8, 245585, 2017 | 41 | 2017 |
| Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity Z Petros, MTM Lee, A Takahashi, Y Zhang, G Yimer, A Habtewold, ... BMC genomics 17, 1-8, 2016 | 41 | 2016 |
| CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans E Aklillu, L Odenthal-Hesse, J Bowdrey, A Habtewold, E Ngaimisi, ... BMC infectious diseases 13, 1-10, 2013 | 36 | 2013 |
| Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study A Habtewold, E Makonnen, W Amogne, G Yimer, G Aderaye, L Bertilsson, ... Pharmacogenomics 16 (10), 1047-1064, 2015 | 32 | 2015 |
| Plasmodium falciparum and Schistosoma mansoni coinfection and the side benefit of artemether-lumefantrine in malaria patients SM Abay, M Tilahun, N Fikrie, A Habtewold The Journal of Infection in Developing Countries 7 (06), 468-474, 2013 | 29 | 2013 |
| Copy number variation of Fc gamma receptor genes in HIV-infected and HIV-tuberculosis co-infected individuals in sub-Saharan Africa LR Machado, J Bowdrey, E Ngaimisi, A Habtewold, O Minzi, E Makonnen, ... PloS one 8 (11), e78165, 2013 | 27 | 2013 |
| SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine E Aklillu, A Habtewold, E Ngaimisi, G Yimer, S Mugusi, W Amogne, ... OMICS: A Journal of Integrative Biology 20 (9), 538-545, 2016 | 26 | 2016 |
| Prevalence and risk factors for efavirenz-based antiretroviral treatment–associated severe vitamin D deficiency: A prospective cohort study H Nylén, A Habtewold, E Makonnen, G Yimer, L Bertilsson, J Burhenne, ... Medicine 95 (34), e4631, 2016 | 22 | 2016 |
| T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART. CF Bekele Y, Yibeltal D, Bobosha K, Andargie TE, Lemma M, Gebre M, Mekonnen ... Sci Rep. 7 (1), 8956, 2017 | 19 | 2017 |
| Genome-wide association and replication study of hepatotoxicity induced by antiretrovirals alone or with concomitant anti-tuberculosis drugs Z Petros, MTM Lee, A Takahashi, Y Zhang, G Yimer, A Habtewold, ... Omics: a journal of integrative biology 21 (4), 207-216, 2017 | 15 | 2017 |
| Long‐term effect of rifampicin‐based anti‐TB regimen coadministration on the pharmacokinetic parameters of efavirenz and 8‐hydroxy‐efavirenz in Ethiopian patients A Habtewold, E Aklillu, E Makonnen, W Amogne, G Yimer, G Aderaye, ... The Journal of Clinical Pharmacology 56 (12), 1538-1549, 2016 | 15 | 2016 |
| Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy: a parallel prospective cohort … S Mugusi, A Habtewold, E Ngaimisi, W Amogne, G Yimer, O Minzi, ... Frontiers in Pharmacology 11, 506486, 2020 | 14 | 2020 |
